论文部分内容阅读
为阐明继发于何杰金氏病治疗后第二种肿瘤的发病率,作者对1965年元月至1976年底住院的676例成人及88例儿童何杰金氏病患者进行了分析。直到1979年分析时患者治疗的情况分三组:单独放疗(RT)236例(占31%),RT加化疗492例(占64%),单独化疗(大多数为联合化疗)36例(占5%)。结果在首次治疗后10年内,全部患者中发生第二种实体瘤的发病率为7.3%,而并发ANLL(急性非淋巴细胞白血病)者占2.4%。单独RT的实体瘤发病率为14.9%而无ANLL发生。单独化疗的患者,无实体瘤发生,仅有一例(5.5%)并发ANLL。RT加化疗的患者,实体瘤发病率为6.2%,而ANLL的发病率为3.5%;其中RT加MOPP(氮芥、长春新碱、甲基苄肼和强的松龙)组,无实体瘤发生,而ANLL的发病率为5.4%;RT加ABVD(14-羟柔毛霉素、博莱霉素、长春花碱和dacarbazine)组则既无实体瘤,也无白血病发生。据此作者提出继发肿瘤的发生与化疗药物有关,具有氮芥及/或甲基苄肼的化疗方案可增加ANLL的发病率。第二种实体瘤共15例,其
To clarify the incidence of secondary tumors following Hodgkin’s disease treatment, the authors analyzed 676 adult and 88 Hodgkin’s disease patients hospitalized from January 1965 to the end of 1976. Until 1979, the analysis of patients’ treatment was divided into three groups: 236 cases (31%) with radiotherapy alone (RT), 492 cases (64%) with RT plus chemotherapy and 36 cases with chemotherapy alone (mostly with combination chemotherapy) 5%). Results The incidence of second solid tumors in all patients was 7.3% within 10 years of initial treatment, with 2.4% of patients with ANLL (acute non-lymphocytic leukemia). The incidence of solid tumors with RT alone was 14.9% without ANLL. In patients with chemotherapy alone, no solid tumors occurred, and only one patient (5.5%) complicated with ANLL. RT plus chemotherapeutic patients, the incidence of solid tumors was 6.2%, while the incidence of ANLL was 3.5%; RT plus MOPP (nitrogen mustard, vincristine, procarbazine and prednisolone) group, no solid tumor , While the incidence of ANLL was 5.4%. RT plus ABVD (14-hydroxyarcirubicin, bleomycin, vinblastine and dacarbazine) groups were neither solid tumors nor leukemias. Accordingly, the authors suggest that the occurrence of secondary tumors is associated with chemotherapeutic drugs, and that chemotherapy regimens with nitrogen mustard and / or procarbazine increase the incidence of ANLL. A total of 15 cases of the second solid tumor, its